

**Association between use of novel glucose-lowering drugs
and COVID-19 hospitalization and death in patients with type 2 diabetes:
a nationwide registry analysis**

Running title: New glucose-lowering drugs and COVID-19

Giulia Ferrannini MD¹, Lars H Lund MD PhD^{1,2}, Lina Benson MSc¹,

Manfredi Rizzo MD PhD³, Wael Almahmeed MD⁴, Giuseppe MC Rosano MD PhD⁵,

Gianluigi Savarese MD PhD^{1,2*}, Francesco Cosentino MD PhD^{1,2*}

* Equal contribution as senior author

¹ Division of Cardiology, Department of Medicine, Karolinska Institute, Stockholm, Sweden

² Heart, Vascular and Neuro Theme, Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden

³ School of Medicine, ProMISE Department, University of Palermo, Palermo, Italy

⁴ Heart and Vascular Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE

⁵ Centre for Clinical and Basic Research, IRCCS San Raffaele Roma, Rome, Italy

Correspondence to:

Francesco Cosentino, MD PhD

Division of Cardiology, Department of Medicine, Karolinska Institutet, Norrbacka S1:02

e-mail: francesco.cosentino@ki.se

Tel: +46 8 517 72 245

Fax: +46 8 34 49 64

Abstract

Aims

Type 2 diabetes (T2DM) in patients with coronavirus disease-19 (COVID-19) is associated with worse prognosis. We separately investigated the associations between the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RA) and dipeptidyl peptidase-4 inhibitors (DPP-4i), and the risk of COVID-19 hospitalization and death.

Methods and results

Patients with T2DM registered in the Swedish National Patient Registry and alive on 1st February 2020 were included. "Incident severe COVID-19" was defined as the first hospitalization and/or death from COVID-19. A modified Poisson regression approach was applied to a 1:1 propensity score-matched population receiving vs. not receiving SGLT2i, GLP-1 RA and DPP-4i to analyze the associations between their use and I) incident severe COVID-19, II) risk of 30-day mortality in patients hospitalized for COVID-19.

Among 344,413 patients, 39,172 (11%) were treated with SGLT2i, 34,290 (10%) with GLP-1 RA and 53,044 (15%) with DPP-4i; 9,538 (2.8%) had incident severe COVID-19 by 15th May 2021. SGLT2i and DPP-4i were associated with a 10% and 11% higher risk of incident severe COVID-19, respectively, whereas there was no association for GLP-1 RA. DPP-4i were also associated with a 10% higher 30-day mortality in patients hospitalized for COVID-19, whereas there was no association for SGLT2i and GLP-1 RA.

Conclusion

SGLT2i and DPP-4i use was associated with higher risk of incident severe COVID-19. DPP-4i use was associated with higher 30-day mortality in patients with COVID-19, whereas SGLT2i use was not. No increased risk for any outcome was observed with GLP-1 RA.

Key words

COVID-19; sodium-glucose cotransporter 2 inhibitors; glucagon-like peptide-1 receptor agonists; dipeptidyl peptidase-4 inhibitors (DPP-4i); hospitalization; mortality.

1. Introduction

The current coronavirus disease 2019 (COVID-19) pandemic, due to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is an ongoing challenge(1). Type 2 diabetes mellitus (T2DM) has been reported as one of the most frequent comorbidities associated with severe COVID-19, conferring a two-fold higher relative risk of severe COVID-19 requiring intensive care unit and in-hospital death(2). Possible mechanisms behind higher morbidity and mortality with COVID-19 in patients with vs. without T2DM are systemic inflammation, immunodeficit and hypercoagulability(3; 4). The cytokine storm in severe COVID-19 involves elevated levels of serum C-reactive protein, interleukin-6 (IL-6), D-dimer and ferritin, which are also observed in the chronic inflammation associated with hyperglycemia(5). Angiotensin Converting Enzyme 2 (ACE2) and Dipeptidyl Peptidase-4 (DPP-4) are two coronavirus receptor proteins that also have a role in glucose homeostasis regulation(6; 7). Finally, observational studies suggested that anti-inflammatory agents used in severe COVID-19 pneumonia, e.g., anti-IL-6 agents, might be less effective in the presence of hyperglycemia(8).

Novel glucose-lowering medications may reduce adverse COVID-19 outcomes because of their anti-inflammatory properties, but the potential role of different pharmacological classes in adverse COVID-19 outcomes has not been systematically investigated(5). DPP-4 inhibitors (DPP-4i) have been suggested to have a beneficial role in T2DM patients hospitalized for COVID-19(5; 9). Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) have several anti-inflammatory properties, which might also be linked with better outcomes(5; 10). Conversely, safety concerns have been raised for SGLT2i and GLP-1 RA, since they increase ACE2 expression which mediates SARS-CoV-2 binding to the cells(11). However,

RAAS inhibitor drugs, which also increase ACE2 expression, do not appear to be associated with increased risk of incident COVID-19 or worse outcomes in prevalent COVID-19(12).

The aim of the current study was to separately investigate the association between SGLT2i, GLP-1 RA and DPP-4i use with (I) incident hospitalization/death for COVID-19 and (II) mortality in patients with COVID-19, in a nationwide cohort of T2DM patients in Sweden.

2. Methods

2.1 Data sources

The analyses were performed using the Swedish National Patient Registry (NPR) linked through the personal identification number to the Cause of Death Registry, the Dispensed Drug Registry, and Statistics Sweden(13). The NPR, the Cause of Death Registry and the Dispensed Drug Registry are administered by the Swedish Board of Health and Welfare (www.socialstyrelsen.se), which collects International Classification of Diseases (ICD-10) diagnoses from all residents in Sweden, at hospitalizations as well as at outpatient non-primary care clinics. The Dispensed Drug Registry contains data for all dispensed prescriptions since 2005. Statistics Sweden collects socioeconomic data of Swedish residents.

2.2 Study population and outcomes

Adult patients with a diagnosis of T2DM in the NPR after 1997 (when ICD-10 was implemented) and who were alive on 01/02/2020 were included in the analyses. Additional exclusion criteria are reported in **Supplementary Table S1**.

Index date was 01/02/2020 (first COVID-19 case in Sweden registered at the end of January 2020).

End of follow-up was 15/05/2021.

Outcomes were incident severe COVID-19 in the overall study population and 30-day all-cause mortality in patients with COVID-19. Incident severe COVID-19 was defined as the first occurrence of a hospitalization with confirmed COVID-19 as main diagnosis in the NPR or

confirmed COVID-19 as underlying cause of death in Cause of Death Registry. In patients hospitalized for COVID-19, In patients hospitalized for COVID-19, subsequent hospitalizations for hypoglycaemia and diabetic ketoacidosis (DKA) were also investigated, with patients censored at death or at end of follow-up.

The percentage of patients still on treatment with the different study drugs was calculated based on those with at least one prescription within 5 months after incident severe COVID-19.

Detailed definitions for comorbidities, COVID-19 disease, and treatments are available in **Supplementary Table S2**.

2.3 Statistical analysis

Baseline characteristics of patients receiving vs. not receiving SGLT2i, GLP-1 RA and DPP-4i, separately, were reported as frequencies (percentages) for categorical variables and as medians (interquartile range-IQR) for continuous variables. Differences were evaluated by standardized mean differences (SMD), where a value <0.1 was considered as non-significant. There was limited missing data from the following variables from Statistics Sweden: country of birth, income, education level, family type (living alone or not) and living in region Stockholm or not. Patients with missing data are excluded from all analyses (**Supplementary Table S1**).

Separate analyses were performed for the three investigated drug classes. In the whole study population, the association between treatment and incident severe COVID-19 was evaluated. In a subset of patients hospitalized for COVID-19 and 30-days follow-up available, the association between the treatment and 30-day all-cause mortality was assessed. The associations were investigated by a modified Poisson regression approach(14), i.e. using Generalized Estimating Equations models with a Poisson distribution and a robust error variance. Adjustment for covariates was performed by propensity score (PS) matching where the PS for the treatment of interest was estimated for each patient by a logistic regression model including the variables indicated with * in **Supplementary Table S3** as covariates, and where age was modelled using cubic splines with four

degrees of freedom. 1:1 matching without replacement, where the PS was allowed to differ by 0.01 or less, was thereafter performed. The ability of the PS-matching to balance the baseline characteristics was assessed by SMD. 1:1 PS-matching was deemed the best option when the balance between groups and the number of patients retained in the analysis is considered. The matched pairs were incorporated in the model using an exchangeable correlation structure.

Consistency analyses were performed 1) in the overall (unmatched) population, adjusting for the individual variables indicated with * in **Supplementary Table S3** rather than matching by PS; and 2) for the analysis with COVID-19 as outcome, using a sub-distributional hazards model, (Fine-Gray model) for time to incident severe COVID-19 where non-COVID-19 death was treated as a competing event.

The associations between each treatment and the outcomes in predefined subgroups were investigated by including an interaction term in the model. One considered subgroup was the Stockholm region since the greatest number of cases was registered there. All analyses were performed using R version 4.0.2.

2.4 Ethics

Patient consent is not required for registration in the national administrative registries. The current analysis was approved by the Swedish Ethics Review Authority and was conducted in accordance with the Declaration of Helsinki.

3. Results

Of 365,537 patients with a diagnosis of T2DM recorded in the NPR between 1997 and 1st February 2020, 344,413 were included in our analysis after applying the exclusion criteria (**Supplementary Table S1**). The median age (IQR) of the study population was 72 (62-79), 42.4% were women; 39,172 (11.4%) were treated with SGLT2i, 34,290 (10%) with GLP-1 RA and 53,044 (15.4%) with DPP-4i.

3.1 Baseline characteristics

The baseline characteristics of patients receiving vs. non-receiving SGLT2i, GLP-1 RA and DPP-4i are reported in **Table 1** and in **Supplementary Table S3**.

SGLT2i users vs. non-users had higher prevalence of obesity and ischemic heart disease, with more frequent prior coronary revascularizations. SGLT2i users were more likely to receive antiplatelet therapy, renin-angiotensin system inhibitors/angiotensin receptor-neprilysin inhibitors (RASi/ARNi), beta blockers, and lipid-lowering drugs compared with non-users. Moreover, patients receiving SGLT2i were more often treated with other glucose-lowering agents, including oral antidiabetics, insulin, GLP-1 RA and DPP-4i.

GLP-1 RA users vs. non-users were younger, with higher education level and income. The prevalence of the analyzed comorbidities was similar in both groups except for history of stroke, atrial fibrillation, previous bleeding events, history of cancer in the last 3 years, dementia and previous stroke being more prevalent among non-users and obesity being more common among users. GLP-1 RA users were more often treated with RASi/ARNi, lipid-lowering drugs, insulin, metformin and SGLT2i but not with other oral antidiabetics.

DPP-4i users vs. non-users were older, with higher prevalence of renal disease, but the other comorbidities did not substantially differ. RASi/ARNi, beta blockers, calcium channel blockers, lipid lowering drugs, diuretics, and oral glucose-lowering agents were all prescribed in higher proportions in users than in non-users.

Baseline characteristics of the subset of patients hospitalized for COVID-19 patients according to the use of the three different drug classes are shown in **Supplementary Table S4**.

3.2 Association between SGLT2i, GLP-1 RA or DPP-4i use and risk of incident severe COVID-19

(Table 2)

Of the 344,413 patients included in our analysis, 9,538 (2.8%) had incident severe COVID-19; among them, 963 (10.1%) were taking SGLT2i, 907 (9.5%) were taking GLP-1 RA and 1,639 (17.2%) were taking DPP-4i.

The risk of incident severe COVID-19 was significantly higher in SGLT2i users vs non-users, with a risk ratio (RR) [95% confidence interval (CI)] of 1.11 [1.02 – 1.22]. The consistency analyses confirmed this significant difference and results were similar across all investigated subgroups (Figure 1).

The use of GLP-1 RA was not significantly associated with risk of incident severe COVID-19 (RR [95% CI]: 1.05 [0.96 – 1.15]), which was confirmed by the competing risk analysis. However, in the consistency analysis in the unmatched population, where adjustments were performed according to individual covariates, GLP-1 RA use was associated with a higher risk of incident severe COVID-19 (RR [95% CI]: 1.10 [1.02 – 1.18]). Among the investigated subgroups, GLP-1 RA treatment was associated with a higher risk of incident severe COVID-19 in the subset without heart failure (RR [95% CI]: 1.12 [1.01-1.24], p-value for interaction 0.015). Results were consistent in the other subgroups (Figure 1).

The use of DPP-4i was associated with a higher risk of incident severe COVID-19 (RR [95% CI]: 1.10 [1.03 – 1.18]), with similar results in the consistency analyses and in all subgroups (Figure 1).

3.3 Outcomes in patients hospitalized for COVID-19 (Table 3)

Overall, 2,975 (31%) deaths occurred in the 9,538 hospitalized patients with COVID-19 as primary diagnosis, with 2,145 deaths (72%) having COVID-19 as the underlying cause of death. In the PS-adjusted analyses there was no significant difference in the risk of 30-day all-cause death in patients receiving vs. not receiving SGLT2i, with a RR [95% CI] of 1.04 [0.85-1.27], and GLP-1 RA with a

RR [95% CI] of 0.88 [0.73-1.07], whereas risk was higher in DPP-4i users vs non-users, with a RR [95% CI] of 1.11 [1.00-1.22]. These results were overall consistent in the subgroups, except for a statistically significant lower risk of 30-days mortality associated with GLP-1 RA use in patients on concomitant metformin therapy (RR [95% CI]: 0.62 [0.45-0.85], interaction $p = 0.003$).

Hospitalizations for hypoglycaemia according to the use of the three different drug classes was very low, with no substantial difference between users and non-users, as presented in **Supplemental Table S5**. There were no hospitalizations for DKA.

As regards treatment continuation, 285 (78%) of the patients who were prescribed an SGLT2i at the index date was still prescribed after five months; the respective results for GLP1-RA and DPP-4i were 250 (77%) and 400 (78%).

4. Discussion

In this nationwide cohort of patients with T2DM, the use of SGLT2i and of DPP-4i was associated with higher risk of incident severe COVID-19, defined as hospitalization for or death from COVID-19, whereas GLP-1 RA use was numerically associated with increased risk but without reaching statistical significance. Among patients hospitalized with COVID-19, the use of DPP-4i, but not of SGLT2i or GLP-1 RA, was associated with higher mortality.

The relationship between the use of glucose-lowering agents and COVID-19-related outcomes is paramount in clinical practice and to policy makers, because of the high and growing prevalence of T2DM and subsequent cardiovascular complications, the increasing use of novel glucose-lowering drugs, the higher COVID-19 mortality observed in patients with T2DM(15), and the recurring and unpredictable waves of COVID-19 despite effective vaccines(16).

As regards SGLT2i, clinical practice guidelines recommend the discontinuation in acute illness due to the increased risk of volume depletion and DKA(17). We observed that their at-home use was associated with an 11% higher risk of incident severe COVID-19, however no hospitalizations for DKA were observed. These findings might be explained by higher hospitalization rates for COVID-

19 in patients treated vs. non-treated with SGLT2i, with the first being at higher CV risk compared with the latter, and therefore more susceptible to a more severe COVID-19. Indeed, in our population, a larger proportion of patients receiving SGLT2i had established atherosclerotic cardiovascular disease and was on treatment with antiplatelet agents, antihypertensive medications, lipid-lowering drugs, and antidiabetics(18). Despite extensive adjustments for these and many other patient characteristics, we were not able to directly assess and therefore adjust for other cardiometabolic risk factors such as glycated hemoglobin (HbA1c) or lipid levels, and thus we cannot rule out that residual confounding, e.g. more severe cardiometabolic disease in SGLT2i users, might explain their 11% higher risk of incident severe COVID-19. However, in patients hospitalized for COVID-19, mortality rates were not higher with SGLT2i. Consistent with these findings, the DARE-19 randomized controlled trial showed no difference between dapagliflozin and placebo in 1,250 patients with cardiometabolic risk factors as regards the risk of new or worsened organ dysfunction, death, and recovery(19). Nonetheless, dapagliflozin was well tolerated and no new safety signals were identified, in accordance with the present study, where just two hospitalizations for hypoglycaemia were reported for SGLT2i users (vs seven in non-users) and there was no hospitalization for DKA. Results of the RECOVERY trial (NCT04381936), which aims to assess whether empagliflozin reduces the risk of death, the length of hospital stay and the need of mechanical ventilation among patients admitted to hospital with COVID-19, will provide further evidence on SGLT2i.

It has been suggested that the pharmacological inhibition of DPP-4 might hinder virus penetration in the target cells, thus conferring a lower risk of incident COVID-19 in DPP-4i users(20). However, later preclinical studies showed that the binding sites for DPP-4i do not overlap with those for viral spike proteins of SARS-CoV-2(21). Observational data are considerably heterogeneous(22). In a large primary care setting in UK, patients prescribed with SGLT2i had a similar risk of confirmed or clinically suspected COVID-19 compared to patients prescribed with DPP4i (23). On the other hand, an observational cohort study on 2.85 million English patients with

T2DM reported adjusted hazard ratios for COVID-19-related death of 0.94 (0.83–1.07) for GLP-1 RA and 1.07 (1.01–1.13) for DPP-4i inhibitors(24).

The current practical recommendations do not mandate the discontinuation of incretin-based therapies in patients with COVID-19(17), and indeed, most of the patients with incident severe COVID-19 in the present study were prescribed the investigated treatments after discharge.

Previous studies on patients with T2DM and confirmed COVID-19 report mixed findings. Meta-analyses reported that the use of DPP-4i(9) and of GLP-1 RA(25) was associated with decreased COVID-19 mortality. In a study conducted in Italy, treatment with sitagliptin was associated with lower mortality and better clinical outcomes compared with standard-of-care treatment(26). Accordingly, a large multinational retrospective cohort study demonstrated that use of GLP-1 RA and DPP-4i was associated with fewer hospital admissions, respiratory complications and mortality(27). Other studies suggested no associations between incretin-based therapies use in COVID-19 and outcomes: a registry-based Danish study did not show any difference in the risk of adverse outcomes between GLP-1 RA or DPP-4i users, and SGLT2i users(28). In the Spanish SEMI-COVID-19 registry no significant associations were found between the use of SGLT2i and DPP-4i and the admission to intensive care units, mechanical ventilation, in-hospital death, development of in-hospital complications and a long-time hospital stay in patients hospitalized for COVID-19(29). A PS-matched analysis of the prospective observational study CORONADO reported no association between DPP-4i use and the composite primary endpoint (tracheal intubation for mechanical ventilation and death within 7 days of admission)(30). Finally, data from 12,446 SARS-CoV-2-positive adults in the National COVID Cohort Collaborative U.S. study showed that GLP-1 RA and SGLT2i use was associated with lower odds of 60-day mortality compared with DPP-4i use(31).

GLP-1 RA use was not associated with incident severe COVID-19 and mortality in patients hospitalized for COVID-19 in the main analysis (i.e., PS-matched), whereas in the adjusted model including all patients the risk associated with GLP1-RA use was 10% higher. The association of

DPP-4i use with incident severe COVID-19 was significant, consistently in the main analysis and in the multi-adjusted analysis. One possible explanation could be that in our study DPP-4i users were significantly older compared with non-users and with SGLT2i and GLP-1 RA users, in accordance with national recommendations in Sweden. Age by itself is an independent risk factor for COVID-19 morbidity and mortality and might be accompanied by other comorbidities and frailty which we could not adjust for. Another possible explanation is that, unlike SGLT2i and most of GLP1-RA, DPP-4i do not provide cardiovascular protection in patients with T2DM, and this might affect the prognosis in patients with severe COVID-19, who are particularly burdened by adverse cardiovascular outcomes(32). Stronger evidence will be provided by ongoing randomized clinical trials on sitagliptin (SIDIACO-RCT, NCT04365517) and linagliptin (NCT04371978, NCT04341935). However, it must be noted that SGLT2i and GLP-1 RA are very effective in reducing cardiovascular risk, which steadily burdens patients with diabetes at least as much as COVID-19 during the pandemic, thus their benefit justifies their continued use.

The present analysis has several strengths. The inclusion of a large nationwide registry population with full coverage warrants high generalizability of our findings. The risk of incident severe COVID-19 is addressed in the general population of T2DM patients, providing a large clinical prospective. PS-matched analyses allowed to adjust for potential known confounders.

Some limitations should be acknowledged. First, the observational nature of this study prevents from assessing causality, i.e. residual confounding and selection bias cannot be rule out. We made all efforts to address this bias by using different models in consistency analyses, however the results were not steadily in accordance: in the fully adjusted models, the association between the single class use and risk for incident severe COVID-19 were statistically significant, suggesting high potential for residual confounding, possibly conferred by indication bias and frailty. Second, the number of quality check on the data obtained by the Swedish Board of Health and Welfare in 2021 was lower than usual due to the urgency of providing information on the pandemics. Third, since patients with COVID-19 were defined based on hospitalization or death for COVID-19, our results

might not be generalizable to COVID-19 patients who were not admitted to the hospital. Although our analyses were adjusted for comorbidities and pharmacological treatments which might serve as proxies of glycaemic control, data on HbA1c levels were missing thus glycaemic control could not be directly assessed. Finally, patients with T2DM only treated in primary care were not included.

In conclusion, in a nationwide real-world population of patients with T2DM, the use of SGLT2i was associated with slightly higher risk of incident COVID-19 hospitalization/death, but not with higher 30-day mortality in patients with COVID-19. GLP-1 RA treatment was not significantly associated with higher risk of COVID-19 hospitalization/death or with increased mortality. The use of DPP-4i was associated with a slightly higher risk of hospitalization/death due to COVID-19 and of 30-day mortality among patients hospitalized with COVID-19. None of the three drug classes was associated with an increased risk of incident severe COVID-19 or death that exceeded 11%. Thus, these observational results should be interpreted with caution because of the high potential of indication bias, i.e. overall increased vulnerability in patients who are prescribed these drugs.

Acknowledgements

Author contributions

G.F. manuscript draft, data interpretation, handling.

L.H.L. conceptualization, data interpretation.

L.B. data analysis and interpretation.

M.R., W.A., G.M.C.R.: data interpretation.

G.S., F.C.: conceptualization, data interpretation.

All authors: critical review.

Funding/financial support

This work was supported by a grant from City Pharmacy, Abu Dhabi, UAE.

Conflict of interest statement

The authors have no conflicts of interest related to this work.

G.M.C.R. and G.S. are Editors of European Heart Journal – Cardiovascular Pharmacotherapy and were not involved in the peer review process or publication decision.

Data availability statement

The data underlying this article are available in the article and in its online supplementary material.

References

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med* 2020;382:727-733
2. Mantovani A, Byrne CD, Zheng MH, Targher G. Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: A meta-analysis of observational studies. *Nutr Metab Cardiovasc Dis* 2020;30:1236-1248
3. Liu D, Wang Y, Zhao B, Lan L, Liu Y, Bao L, Chen H, Yang M, Li Q, Zeng Y. Overall reduced lymphocyte especially T and B subsets closely related to the poor prognosis and the disease severity in severe patients with COVID-19 and diabetes mellitus. *Diabetol Metab Syndr* 2021;13:5
4. Du F, Liu B, Zhang S. COVID-19: the role of excessive cytokine release and potential ACE2 down-regulation in promoting hypercoagulable state associated with severe illness. *J Thromb Thrombolysis* 2021;51:313-329
5. Katsiki N, Ferrannini E. Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era? *J Diabetes Complications* 2020;34:107723
6. Drucker DJ. Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications. *Endocr Rev* 2020;41
7. Li Y, Zhang Z, Yang L, Lian X, Xie Y, Li S, Xin S, Cao P, Lu J. The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2 Spike. *iScience* 2020;23:101160
8. Marfella R, Paolisso P, Sardu C, Bergamaschi L, D'Angelo EC, Barbieri M, Rizzo MR, Messina V, Maggi P, Coppola N, Pizzi C, Biffi M, Viale P, Galie N, Paolisso G. Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients. *Diabetes Metab* 2020;46:403-405
9. Yang Y, Cai Z, Zhang J. DPP-4 inhibitors may improve the mortality of coronavirus disease 2019: A meta-analysis. *PLoS One* 2021;16:e0251916
10. Abramczyk U, Kuzan A. What Every Diabetologist Should Know about SARS-CoV-2: State of Knowledge at the Beginning of 2021. *J Clin Med* 2021;10
11. Pal R, Bhadada SK. Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? *Diabetes Res Clin Pract* 2020;163:108146
12. Savarese G, Benson L, Sundstrom J, Lund LH. Association between renin-angiotensin-aldosterone system inhibitor use and COVID-19 hospitalization and death: a 1.4 million patient nationwide registry analysis. *Eur J Heart Fail* 2021;23:476-485

13. Ludvigsson JF, Almqvist C, Bonamy AK, Ljung R, Michaelsson K, Neovius M, Stephansson O, Ye W. Registers of the Swedish total population and their use in medical research. *Eur J Epidemiol* 2016;31:125-136
14. Zou G. A modified poisson regression approach to prospective studies with binary data. *Am J Epidemiol* 2004;159:702-706
15. Barron E, Bakhai C, Kar P, Weaver A, Bradley D, Ismail H, Knighton P, Holman N, Khunti K, Sattar N, Wareham NJ, Young B, Valabhji J. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. *Lancet Diabetes Endocrinol* 2020;8:813-822
16. Al Mahmeed W, Al-Rasadi K, Banerjee Y, Ceriello A, Cosentino F, Galia M, Goh SY, Kempler P, Lessan N, Papanas N, Rizvi AA, Santos RD, Stoian AP, Toth PP, Rizzo M, COvid CAPoleoS. Promoting a Syndemic Approach for Cardiometabolic Disease Management During COVID-19: The CAPISCO International Expert Panel. *Front Cardiovasc Med* 2021;8:787761
17. Bornstein SR, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld AL, Boehm B, Amiel S, Holt RI, Skyler JS, DeVries JH, Renard E, Eckel RH, Zimmet P, Alberti KG, Vidal J, Geloneze B, Chan JC, Ji L, Ludwig B. Practical recommendations for the management of diabetes in patients with COVID-19. *Lancet Diabetes Endocrinol* 2020;8:546-550
18. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Jüni P, Lettino M, Marx N, Mellbin LG, Östgren CJ, Rocca B, Roffi M, Sattar N, Seferović PM, Sousa-Uva M, Valensi P, Wheeler DC. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J* 2020;41:255-323
19. Kosiborod MN, Esterline R, Furtado RHM, Oscarsson J, Gasparyan SB, Koch GG, Martinez F, Mukhtar O, Verma S, Chopra V, Buenconsejo J, Langkilde AM, Ambery P, Tang F, Gosch K, Windsor SL, Akin EE, Soares RVP, Moia DDF, Aboudara M, Hoffmann Filho CR, Feitosa ADM, Fonseca A, Garla V, Gordon RA, Javaheri A, Jaeger CP, Leaes PE, Nassif M, Pursley M, Silveira FS, Barroso WKS, Lazcano Soto JR, Nigro Maia L, Berwanger O. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Diabetes Endocrinol* 2021;9:586-594
20. Filardi T, Morano S. COVID-19: is there a link between the course of infection and pharmacological agents in diabetes? *J Endocrinol Invest* 2020;43:1053-1060
21. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Muller MA, Drosten C, Pohlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* 2020;181:271-280 e278
22. Bonora BM, Avogaro A, Fadini GP. Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis. *J Endocrinol Invest* 2021;44:1379-1386
23. Sainsbury C, Wang J, Gokhale K, Acosta-Mena D, Dhalla S, Byne N, Chandan JS, Anand A, Cooper J, Okoth K, Subramanian A, Bangash MN, Taverner T, Hanif W, Ghosh S, Narendran P, Cheng KK, Marshall T, Gkoutos G, Toulis K, Thomas N, Tahrani A, Adderley NJ, Haroon S, Nirantharakumar K. Sodium-glucose co-transporter-2 inhibitors and susceptibility to COVID-19: A population-based retrospective cohort study. *Diabetes Obes Metab* 2021;23:263-269
24. Khunti K, Knighton P, Zaccardi F, Bakhai C, Barron E, Holman N, Kar P, Meace C, Sattar N, Sharp S, Wareham NJ, Weaver A, Woch E, Young B, Valabhji J. Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England. *Lancet Diabetes Endocrinol* 2021;9:293-303
25. Hariyanto TI, Intan D, Hananto JE, Putri C, Kurniawan A. Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): A systematic review, meta-analysis, and meta-regression. *Diabetes Res Clin Pract* 2021;179:109031

26. Solerte SB, D'Addio F, Trevisan R, Lovati E, Rossi A, Pastore I, Dell'Acqua M, Ippolito E, Scaranna C, Bellante R, Galliani S, Dodesini AR, Lepore G, Geni F, Fiorina RM, Catena E, Corsico A, Colombo R, Mirani M, De Riva C, Oleandri SE, Abdi R, Bonventre JV, Rusconi S, Folli F, Di Sabatino A, Zuccotti G, Galli M, Fiorina P. Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study. *Diabetes Care* 2020;43:2999-3006
27. Nyland JE, Raja-Khan NT, Bettermann K, Haouzi PA, Leslie DL, Kraschnewski JL, Parent LJ, Grigson PS. Diabetes, Drug Treatment and Mortality in COVID-19: A Multinational Retrospective Cohort Study. *Diabetes* 2021;
28. Israelsen SB, Pottegård A, Sandholdt H, Madsbad S, Thomsen RW, Benfield T. Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2. *Diabetes Obes Metab* 2021;23:1397-1401
29. Pérez-Belmonte LM, Torres-Peña JD, López-Carmona MD, Ayala-Gutiérrez MM, Fuentes-Jiménez F, Huerta LJ, Muñoz JA, Rubio-Rivas M, Madrazo M, Garcia MG, Montes BV, Sola JF, Ena J, Ferrer RG, Pérez CM, Ripper CJ, Lecumberri JN, Acedo IEA, Canteli SP, Cosío SF, Martínez FA, Rodríguez BC, Pérez-Martínez P, Ramos-Rincón JM, Gómez-Huelgas R. Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study. *BMC Med* 2020;18:359
30. Roussel R, Darmon P, Pichelin M, Goronflot T, Abouleka Y, Ait Bachir L, Allix I, Ancelle D, Barraud S, Bordier L, Carlier A, Chevalier N, Coffin-Boutreux C, Cosson E, Dorange A, Dupuy O, Fontaine P, Fremy B, Galtier F, Germain N, Guedj AM, Larger E, Laugier-Robiofle S, Laviolle B, Ludwig L, Monier A, Montanier N, Moulin P, Moura I, Prevost G, Reznik Y, Sabbah N, Saulnier PJ, Serusclat P, Vatiez C, Wargny M, Hadjadj S, Gourdy P, Cariou B. Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study. *Diabetes Obes Metab* 2021;23:1162-1172
31. Kahkoska AR, Abrahamsen TJ, Alexander GC, Bennett TD, Chute CG, Haendel MA, Klein KR, Mehta H, Miller JD, Moffitt RA, Stürmer T, Kvist K, Buse JB. Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium-Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes. *Diabetes Care* 2021;
32. Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. *Nat Rev Cardiol* 2020;17:543-558




Figure 1

Forest plots of the association between SGLT2i, GLP-1 RA and DPP-4i and incident severe COVID-19 in the whole propensity-score matched cohort and in relevant subgroups.

Legend: HF: heart failure; IHD: ischemic heart disease; SGLT2i: sodium-glucose cotransporter 2 inhibitors; GLP-1 RA: glucagon-like peptide-1 receptor agonists; DPP-4i: dipeptidyl peptidase-4 inhibitors.

ORIGINAL UNEDITED MANUSCRIPT

Table 1 Baseline characteristics of patients with type 2 diabetes according to the use of SGLT2i, GLP-1 RA and DPP-4i. Categorical variables are presented with n (%) and continuous variables with median [q1-q3].

VARIABLE	SGLT2i No	SGLT2i Yes	SMD	GLP1-RA No	GLP1-RA Yes	SMD	DPP-4i No	DPP-4i Yes	SMD
Age	72.0 [63.0, 79.0]	66.0 [59.0, 73.0]	0.433	72.0 [63.0, 79.0]	66.0 [57.0, 73.0]	0.502	71.0 [62.0, 78.0]	73.0 [65.0, 79.0]	0.155
Male sex	172002 (56.3)	26461 (67.6)	0.232	178181 (57.5)	20282 (59.1)	0.034	167018 (57.3)	31445 (59.3)	0.040
Main cardiovascular comorbidities									
Atrial fibrillation	55315 (18.1)	5765 (14.7)	0.092	56307 (18.2)	4773 (13.9)	0.116	51080 (17.5)	10000 (18.9)	0.034
Heart failure	44595 (14.6)	5286 (13.5)	0.032	45462 (14.7)	4419 (12.9)	0.051	41379 (14.2)	8502 (16.0)	0.051
Hypertension	214204 (70.2)	27177 (69.4)	0.017	216942 (70.0)	24439 (71.3)	0.029	202744 (69.6)	38637 (72.8)	0.072
Ischaemic heart disease	80260 (26.3)	13218 (33.7)	0.163	84600 (27.3)	8878 (25.9)	0.031	78691 (27.0)	14787 (27.9)	0.019
Previous Stroke/TIA	50345 (16.5)	5020 (12.8)	0.104	51456 (16.6)	3909 (11.4)	0.150	46668 (16.0)	8697 (16.4)	0.010
Pharmacological therapy									
Anticoagulant	55968 (18.3)	6132 (15.7)	0.071	56868 (18.3)	5232 (15.3)	0.082	51876 (17.8)	10224 (19.3)	0.038
Antiplatelet	100067 (32.8)	15653 (40.0)	0.150	104173 (33.6)	11547 (33.7)	0.002	96678 (33.2)	19042 (35.9)	0.057
Beta blockers	138010 (45.2)	19816 (50.6)	0.108	141082 (45.5)	16744 (48.8)	0.067	130696 (44.9)	27130 (51.1)	0.126
Lipid-lowering	185554 (60.8)	30415 (77.6)	0.371	190623 (61.5)	25346 (73.9)	0.269	177739 (61.0)	38230 (72.1)	0.236
MRA	21172 (6.9)	3423 (8.7)	0.067	21620 (7.0)	2975 (8.7)	0.064	20479 (7.0)	4116 (7.8)	0.028
RASi/ARNi	189049 (61.9)	28361 (72.4)	0.224	192892 (62.2)	24518 (71.5)	0.199	180954 (62.1)	36456 (68.7)	0.140

Abbreviations

DPP-4i: dipeptidyl peptidase-4 inhibitors; GLP-1 RA: glucagon-like peptide-1 receptor agonists; MRA: mineralocorticoid receptor antagonists; RASi/ARNi: renin-angiotensin system inhibitors/ angiotensin receptor-neprilysin inhibitors; SGLT2i: Sodium-glucose cotransporter 2 inhibitors; SMD standardised mean difference; TIA: transitory ischaemic attack.

ORIGINAL UNEDITED MANUSCRIPT

Table 2. Association between SGLT2i, GLP1-RA or DPP-4i use and risk of incident COVID-19 outcome, i.e. presence of a hospitalization with confirmed COVID-19 as main diagnosis in the National Patient Registry or as confirmed COVID-19 as underlying cause of death in Cause of Death Registry.

Model	SGLT2i No	SGLT2i Yes	p-value	GLP1-RA No	GLP1-RA Yes	p-value	DPP-4i No	DPP-4i Yes	p-value
Matched, n (%) event	864 (2.2)	962 (2.5)		862 (2.5)	906 (2.7)		1485 (2.8)	1639 (3.1)	
RR (95% CI)	ref	1.11 (1.02-1.22)	0.020	ref	1.05 (0.96-1.15)	0.289	ref	1.10 (1.03-1.18)	0.005
Competing risk HR (95% CI)	ref	1.11 (1.02-1.22)	0.021	ref	1.05 (0.96-1.15)	0.290	ref	1.11 (1.03-1.19)	0.005
All patients, n (%) event	8575 (2.8)	963 (2.5)		8631 (2.8)	907 (2.7)		7899 (2.7)	1639 (3.1)	
Crude RR (95% CI)	ref	0.88 (0.82-0.93)	<0.001	ref	0.95 (0.89-1.02)	0.140	ref	1.14 (1.08-1.20)	<0.001
Adjusted RR (95% CI)	ref	1.09 (1.02-1.16)	0.017	ref	1.10 (1.02-1.18)	0.010	ref	1.15 (1.09-1.22)	<0.001

ORIGINAL UNEDITED MANUSCRIPT

Table 3. Association between SGLT2i, GLP1-RA and DPP-4i use and risk of all-cause death within 30 days in patients with COVID-19.

Model	SGLT2i No	SGLT2i Yes	p-value	GLP1-RA No	GLP1-RA Yes	p-value	DPP-4i No	DPP-4i Yes	p-value
Matched, n (%) event	146 (16.9)	152 (17.6)		169 (20.8)	149 (18.3)		489 (31.7)	541 (35.1)	
RR (95% CI)	ref	1.04 (0.85-1.27)	0.694	ref	0.88 (0.73-1.07)	0.201	ref	1.11 (1.00-1.22)	0.046
All patients, n (%) event	2823 (34.7)	152 (17.3)		2823 (34.5)	152 (18.2)		2432 (32.6)	543 (35.1)	
Crude RR (95% CI)	ref	0.50 (0.43-0.58)	<0.001	ref	0.53 (0.46-0.61)	<0.001	ref	1.08 (1.00-1.16)	0.059
Adjusted RR (95% CI)	ref	0.91 (0.79-1.05)	0.183	ref	0.91 (0.79-1.04)	0.155	ref	1.05 (0.98-1.12)	0.202

ORIGINAL UNEDITED MANUSCRIPT